GWN Securities Inc. Cuts Holdings in TG Therapeutics, Inc. $TGTX

GWN Securities Inc. decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 60.6% in the third quarter, Holdings Channel reports. The firm owned 21,182 shares of the biopharmaceutical company’s stock after selling 32,592 shares during the quarter. GWN Securities Inc.’s holdings in TG Therapeutics were worth $765,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Signature Wealth Management Partners LLC boosted its position in shares of TG Therapeutics by 3.7% during the third quarter. Signature Wealth Management Partners LLC now owns 11,180 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 400 shares during the last quarter. Teacher Retirement System of Texas lifted its stake in TG Therapeutics by 1.0% during the 2nd quarter. Teacher Retirement System of Texas now owns 40,212 shares of the biopharmaceutical company’s stock valued at $1,447,000 after acquiring an additional 417 shares during the period. Louisiana State Employees Retirement System boosted its holdings in shares of TG Therapeutics by 0.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 63,400 shares of the biopharmaceutical company’s stock valued at $2,282,000 after acquiring an additional 500 shares during the last quarter. Kingswood Wealth Advisors LLC boosted its holdings in shares of TG Therapeutics by 6.4% during the 2nd quarter. Kingswood Wealth Advisors LLC now owns 8,284 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 500 shares during the last quarter. Finally, New York State Teachers Retirement System grew its stake in shares of TG Therapeutics by 0.4% in the second quarter. New York State Teachers Retirement System now owns 120,864 shares of the biopharmaceutical company’s stock worth $4,350,000 after acquiring an additional 500 shares during the period. 58.58% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Yann Echelard sold 5,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director directly owned 223,816 shares in the company, valued at $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is currently owned by corporate insiders.

TG Therapeutics Trading Up 6.0%

Shares of NASDAQ:TGTX opened at $29.54 on Thursday. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $46.48. The company has a market cap of $4.69 billion, a PE ratio of 10.63 and a beta of 1.86. The stock has a 50 day moving average of $30.85 and a 200 day moving average of $32.58. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $0.24 by $2.19. The business had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The company’s revenue for the quarter was up 92.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.02 earnings per share. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. B. Riley raised TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. HC Wainwright started coverage on TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 target price on the stock. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, December 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.75.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Preliminary Q4 & full‑year 2025 revenue beat and bullish 2026 outlook — management reported preliminary net product revenue above guidance and gave a positive 2026 revenue target, and highlighted multiple upcoming Briumvi development milestones that could drive future sales and valuation upside. TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
• Positive Sentiment: Company press release with preliminary fourth-quarter and full‑year 2025 net product revenue and 2026 revenue guidance — the formal release provided the numbers investors reacted to and listed anticipated development milestones tied to Briumvi. TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
• Positive Sentiment: Retail trader interest and social‑media chatter have picked up, contributing to heavier volume and momentum in the stock — increased retail attention can amplify short‑term moves and drew coverage explaining why traders are piling in. Retail traders are piling into TG Therapeutics – what’s driving the chatter?
• Positive Sentiment: Unusual options activity — heavy call buying (roughly 7,870 calls traded, ~119% above typical volume) signals speculative bullish bets and may be amplifying the upward price pressure as traders position for further gains.
• Neutral Sentiment: Company updated FY‑2025 and FY‑2026 earnings guidance (EPS entries reported but not detailed in the feed) — the guidance update underpins the revenue narrative but the lack of published EPS numbers in the summary leaves the magnitude of profit guidance unclear.
• Neutral Sentiment: TG’s presentation at the J.P. Morgan Healthcare Conference was posted/transcribed — useful for longer‑term investors to review management’s messaging on commercial traction and pipeline timelines, but it contains no surprise negatives. TG Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Heightened retail and options-driven flows raise short‑term volatility and the risk of sharp reversals — momentum may be disconnected from fundamentals until official audited results, detailed EPS guidance, or clinical milestones are delivered.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.